Graham Capital Management L.P. Acquires 4,869 Shares of GeneDx Holdings Corp. (NASDAQ:WGS)

Graham Capital Management L.P. boosted its stake in GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) by 38.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 17,453 shares of the company's stock after acquiring an additional 4,869 shares during the period. Graham Capital Management L.P. owned 0.06% of GeneDx worth $1,341,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in GeneDx by 18.5% in the fourth quarter. Vanguard Group Inc. now owns 1,006,210 shares of the company's stock valued at $77,337,000 after buying an additional 156,768 shares during the period. William Blair Investment Management LLC acquired a new position in GeneDx in the fourth quarter valued at approximately $51,496,000. Lord Abbett & CO. LLC acquired a new position in GeneDx in the fourth quarter valued at approximately $48,458,000. Fred Alger Management LLC lifted its stake in GeneDx by 38.5% in the fourth quarter. Fred Alger Management LLC now owns 546,054 shares of the company's stock valued at $41,970,000 after buying an additional 151,824 shares during the period. Finally, Science & Technology Partners L.P. acquired a new position in GeneDx in the fourth quarter valued at approximately $30,821,000. 61.72% of the stock is currently owned by institutional investors.

Insider Activity

In other news, CFO Kevin Feeley sold 922 shares of the stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $94.72, for a total value of $87,331.84. Following the completion of the sale, the chief financial officer now owns 5,446 shares in the company, valued at $515,845.12. This represents a 14.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Katherine Stueland sold 2,731 shares of the stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $94.73, for a total transaction of $258,707.63. Following the completion of the sale, the chief executive officer now owns 7,752 shares of the company's stock, valued at approximately $734,346.96. This represents a 26.05% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 139,390 shares of company stock worth $13,043,288 over the last quarter. Insiders own 29.60% of the company's stock.

GeneDx Stock Up 7.4%

Shares of GeneDx stock traded up $4.70 during trading hours on Friday, reaching $68.31. The company's stock had a trading volume of 1,411,729 shares, compared to its average volume of 754,051. GeneDx Holdings Corp. has a one year low of $19.16 and a one year high of $117.75. The company has a market capitalization of $1.95 billion, a P/E ratio of -34.85 and a beta of 1.96. The stock's fifty day simple moving average is $87.10 and its two-hundred day simple moving average is $82.61. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.27 and a current ratio of 2.40.

GeneDx (NASDAQ:WGS - Get Free Report) last announced its earnings results on Wednesday, April 30th. The company reported $0.28 EPS for the quarter, beating the consensus estimate of $0.11 by $0.17. The company had revenue of $87.12 million during the quarter, compared to the consensus estimate of $79.90 million. GeneDx had a negative net margin of 17.12% and a positive return on equity of 3.33%. On average, research analysts forecast that GeneDx Holdings Corp. will post 0.97 earnings per share for the current year.

Wall Street Analyst Weigh In

WGS has been the topic of several recent analyst reports. Jefferies Financial Group raised GeneDx from a "hold" rating to a "buy" rating and set a $80.00 price target on the stock in a research note on Friday, May 9th. TD Securities reduced their price target on shares of GeneDx from $135.00 to $110.00 and set a "buy" rating for the company in a research report on Thursday, May 1st. The Goldman Sachs Group boosted their price target on shares of GeneDx from $70.00 to $80.00 and gave the company a "neutral" rating in a research note on Wednesday, February 19th. Wells Fargo & Company dropped their price objective on shares of GeneDx from $105.00 to $78.00 and set an "equal weight" rating on the stock in a research note on Thursday, May 1st. Finally, Guggenheim started coverage on shares of GeneDx in a research note on Thursday. They issued a "buy" rating and a $88.00 price objective on the stock. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, GeneDx currently has a consensus rating of "Moderate Buy" and a consensus price target of $86.75.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.